Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jan 10;7:40070. doi: 10.1038/srep40070

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2017, The Author(s)

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

BITC also inhibits growth and induces apoptosis in p53-mutant breast cancer cells and p53-null cells. (A,B,C) MCF7 and HBL100 cells were transiently transfected with p53-siRNA and control-si for 48 h and subjected to clonogenicity (A), soft-agar colony formation (B), and TUNEL staining in the presence of vehicle (C) or 2.5 μM BITC as indicated. *P < 0.001, compared with vehicle controls. (D) MDA-MB-231 cells were treated with various concentration of BITC and subjected to clonogenicity assay. (E) Soft-agar colony-formation of MDA-MB-231 cells treated with BITC for three weeks. Histogram represents average number of colonies counted (in six micro-fields). *P < 0.001, compared with controls. Vehicle-treated cells, denoted with the letter “C”. (F) MDA-MB-231 cells were treated with 2.5 μM BITC and subjected to Annexin V/PI staining. *p < 0.01, compared with controls. (G) MDA-MB-468, BT474, T47D and Hs578t cells were treated with various concentration of BITC as indicated and subjected to XTT assay. *P < 0.01, compared with controls. Vehicle-treated cells are denoted with the letter “C”. (H) p53 mutant breast cancer cells were treated with various concentration of BITC as indicated and subjected to clonogenicity assay. (I) Total protein was isolated from HCT116-p53 ^(+/+) and HCT116-p53 ^(−/−) cells and immunoblotted for p53 expression. HCT116-p53 ^(+/+) and HCT116-p53 ^(−/−) cells were also subjected to immunofluorescence analysis for p53 expression. (J) HCT116-p53 ^(+/+) and HCT116-p53 ^(−/−) cells were treated with 2.5 μM BITC and subjected to soft-agar colony formation assay. *p < 0.001, compared with controls. Vehicle-treated cells are denoted with C. (K) HCT116-p53 ^(+/+) and HCT116-p53 ^(−/−) cells were treated with 2.5 μM BITC and subjected to TUNEL assay. *p < 0.005, compared with controls. Vehicle-treated cells are denoted with C.